In trading on Thursday, shares of the GraniteShares YieldBOOST MSTR ETF (Symbol: MTYY) entered into oversold territory, changing hands as low as $4.62 per share. We define oversold territory using the Relative Strength Index, or RSI, which is a technical analysis indicator used
In trading on Thursday, shares of the GraniteShares YieldBOOST MSTR ETF (Symbol: MTYY) entered into oversold territory, changing hands as low as $4.62 per share. We define oversold territory using the Relative Strength Index, or RSI, which is a technical analysis indicator used
Andrii Yalanskyi/iStock via Getty Images Investment Overview The stock of ImmunityBio, Inc. ( IBRX ) has risen in value by ~80% since I last covered the company in January of this year , upgrading to a Buy rating - after two prior Hold calls. Immunity stock is currently priced at $7.3 per share, and the San Diego, California based biotechs' market cap valuation is presently ~$7.9bn. Stock is now u...
Andrii Yalanskyi/iStock via Getty Images Investment Overview The stock of ImmunityBio, Inc. ( IBRX ) has risen in value by ~80% since I last covered the company in January of this year , upgrading to a Buy rating - after two prior Hold calls. Immunity stock is currently priced at $7.3 per share, and the San Diego, California based biotechs' market cap valuation is presently ~$7.9bn. Stock is now up >250% year-to-date, >180% on a six-month basis, and >140% on a one-year basis, although on a one-month basis, it is down nearly 30%, having reached highs of nearly $12 per share in late February. Let's remind ourselves of the company's core business, as per its 2025 annual report / 10-K submission : ANKTIVA is our lead biologic product and a first-in-class IL-15 receptor superagonist antibody-cytokine fusion protein. We are commercializing ANKTIVA for the treatment of BCG-unresponsive NMIBC CIS (non muscle invasive bladder cancer, carcinoma in situ) with or without papillary tumors. ANKTIVA has received FDA Breakthrough Therapy designation for use in BCG-unresponsive NMIBC CIS in adult patients with or without papillary tumors. ANKTIVA is now approved in the U.S., UK, and Saudi Arabia for BCG-unresponsive NMIBC CIS with or without papillary tumors. In February 2026, the European Commission granted conditional marketing authorization in the EU for ANKTIVA for the same indication. Several positive pieces of news-flow have underpinned the stunning rise in the stock price over the past year. Immunity's Lung Cancer Data Triggers Bull Run At the end of 2025, shares traded ~$2, but on January 13th this year, the company shared some updates in relation to Anktiva as a potential therapy for non-small cell lung cancer ("NSCLC"), one of the largest indications in oncology. In combo with a checkpoint inhibitor, i.e., Merck's ( MRK ) PD-1 targeting Keytruda (pembrolizumab), or Bristol-Myers Squibb's ( BMY ) Opdivo (nivolumab), Anktiva demonstrated statistically significant immune rest...
alexsl Zoom Communications ( ZM ) Chief Operating Officer Aparna Bawa is set to resign next month, a company filing said on Thursday. Bawa notified the company on March 30, and she will step down effective as of May 8. Her decision was not the result of any disagreement with the company, Zoom added. More on Zoom Communications Zoom: Undervalued And Underestimated - Even Without The Anthropic Stake...
alexsl Zoom Communications ( ZM ) Chief Operating Officer Aparna Bawa is set to resign next month, a company filing said on Thursday. Bawa notified the company on March 30, and she will step down effective as of May 8. Her decision was not the result of any disagreement with the company, Zoom added. More on Zoom Communications Zoom: Undervalued And Underestimated - Even Without The Anthropic Stake Zoom: 35% Net Cash Plus $4 Billion Stake In Anthropic Zoom Communications, Inc. (ZM) Presents at Morgan Stanley Technology, Media & Telecom Conference 2026 Transcript Zoom, Freshworks among companies that may see 'meaningful' growth via buybacks, Needham says Zoom showing 'impressive progress' putting AI into products and monetizing it: BNP
Trump Admin Revamps Steel, Aluminum, Copper Tariffs; Imposes 100% Duties On Patented Drugs The Trump administration on Thursday announced a pair of tariff actions under national-security authority, maintaining core 50% duties on many imported steel, aluminum and copper products while overhauling the rules to exempt goods containing negligible amounts of those metals and imposing 100% tariffs on im...
Trump Admin Revamps Steel, Aluminum, Copper Tariffs; Imposes 100% Duties On Patented Drugs The Trump administration on Thursday announced a pair of tariff actions under national-security authority, maintaining core 50% duties on many imported steel, aluminum and copper products while overhauling the rules to exempt goods containing negligible amounts of those metals and imposing 100% tariffs on imported patented pharmaceuticals that do not meet new domestic production or pricing conditions. President Donald Trump pauses as he finishes speaking about the Iran war from the Cross Hall of the White House in Washington on April 1, 2026. Alex Brandon-Pool/Getty Images The pharmaceutical measure targets branded drugs and active ingredients brought in by companies that have neither struck “most-favored-nation” pricing deals with the U.S. government nor committed to manufacturing in the United States. Exemptions will be honored for firms that reach such agreements or are already building or expanding U.S. plants . The policy gives large drugmakers 120 days and smaller ones 180 days to comply. Generics and certain trade-agreement partners are largely unaffected. Exceptions were also granted, lowering tariffs to 15 percent - for the European Union, Switzerland, Japan, and South Korea, and a 10 percent levy for the United Kingdom. Reduced rates reflect prior commitments with trading partners, according to a senior administration official. The UK was awarded a lower tariff “because they were the first ones who did this deal, and they committed to raise their prices for pharmaceuticals , and they have actually done so,” the official told reporters during a background call on April 2. Trump negotiated deals with 13 pharmaceutical companies over the past year, securing $400 billion in domestic manufacturing investments, the Epoch Times reports. In tandem, the White House released updated fact sheets detailing changes to Section 232 tariffs on steel, aluminum and copper and their de...
Applied Optoelectronics ( AAOI ) on Thursday said that it has received a new $71 million order for 800G single-mode data center transceivers from a major hyperscale customer. The latest order brings total orders from the customer since mid-March to $124 million and is expected to more than double the company’s existing backlog from that client. The company said it expects to begin deliveries in th...
Applied Optoelectronics ( AAOI ) on Thursday said that it has received a new $71 million order for 800G single-mode data center transceivers from a major hyperscale customer. The latest order brings total orders from the customer since mid-March to $124 million and is expected to more than double the company’s existing backlog from that client. The company said it expects to begin deliveries in the second quarter, complete the initial order in the third quarter, and fulfill the new order by year-end. It also recently shipped 10,000 units of 800G transceivers to another hyperscale data center customer. AAOI +2.82% after hours to $106.8. Source: Press Release More on Applied Optoelectronics Why I'm Buying Applied Optoelectronics, Despite Its Dark History Applied Optoelectronics: The Future For Light Is Bright I Was Early On Applied Optoelectronics, Here's What's Next Memory, storage and optical stock declines drag down chip sector Optical, networking stocks surge after Applied Optoelectronics reveals hyperscaler order
georgeclerk/E+ via Getty Images TFS Financial ( TFSL ) on Thursday said CFO Meredith Weil is set to retire, effective January 2027. James LaRocca, who will join the company as vice president on June 29, 2026, is anticipated to succeed Weil as CFO upon her retirement. Most recently, LaRocca held the post of executive vice president and CFO at Westfield Bank in Westfield Center, Ohio. More on TFS Fi...
georgeclerk/E+ via Getty Images TFS Financial ( TFSL ) on Thursday said CFO Meredith Weil is set to retire, effective January 2027. James LaRocca, who will join the company as vice president on June 29, 2026, is anticipated to succeed Weil as CFO upon her retirement. Most recently, LaRocca held the post of executive vice president and CFO at Westfield Bank in Westfield Center, Ohio. More on TFS Financial Seeking Alpha’s Quant Rating on TFS Financial Historical earnings data for TFS Financial Dividend scorecard for TFS Financial Financial information for TFS Financial